<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04690192</url>
  </required_header>
  <id_info>
    <org_study_id>IHBDH-IIT002</org_study_id>
    <nct_id>NCT04690192</nct_id>
  </id_info>
  <brief_title>CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma</brief_title>
  <official_title>CNCT19 Following Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Aggressive B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zou Dehui</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juventas Cell Therapy Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to explore the safety and efficacy of CNCT19 (a&#xD;
      second-generation anti-CD19 CAR T-cell using 4-1BB as co-stimulatory domain provided by&#xD;
      Juventas, Tianjin, China) infusion following ASCT in patients with relapsed or refractory&#xD;
      B-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, non-randomized, open-label, prospective clinical trial to evaluate&#xD;
      the safety and efficacy of CNCT19 infusion following high-dose chemotherapy and autologous&#xD;
      stem-cell transplantation (HDT/ASCT) in patients with relapsed or refractory B-cell lymphoma.&#xD;
      CNCT19 cells will be infused on day +3 (±1d) with a fixed dose of 2×10^6/kg. The study will&#xD;
      assess the safety and efficacy of this combinational therapy, including the incidence and&#xD;
      severity of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity&#xD;
      syndrome (ICANS), hematological, and other non-hematological toxicities, and objective&#xD;
      response rates and complete response rates and survivals of the subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants experiencing adverse events</measure>
    <time_frame>from the first day of high-dose chemotherapy until 2 years post CNCT19 infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) Rate</measure>
    <time_frame>2 years post CNCT19 infusion</time_frame>
    <description>Complete Response rate is defined as the incidence of a CR per the Lugano Classification (Cheson et al, 2014), as determined by study investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>2 years post CNCT19 infusion</time_frame>
    <description>ORR is defined as the incidence of either a CR or a partial response (PR) per the Lugano Classification as determined by study investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>2 years post CNCT19 infusion</time_frame>
    <description>PFS is defined as the time from the CNCT19 infusion date to the date of disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>2 years post CNCT19 infusion</time_frame>
    <description>DOR is defined only for participants who experience an objective response after CNCT19 infusion and is the time from the first objective response to disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival (DFS)</measure>
    <time_frame>2 years post CNCT19 infusion</time_frame>
    <description>DFS is defined only for participants who achieve complete response after CNCT19 infusion and is the time from complete response to disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years post CNCT19 infusion</time_frame>
    <description>OS is defined as the time from CNCT19 infusion to the date of death from any cause.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Levels of CNCT19 in blood</measure>
    <time_frame>2 years post CNCT19 infusion</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Levels of cytokines in serum</measure>
    <time_frame>1 month post CNCT19 infusion</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Levels of lymphocyte subsets in blood</measure>
    <time_frame>1 year post CNCT19 infusion</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>CNCT19 following ASCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive high-dose chemotherapy followed by stem-cell reinfusion, and a fixed dose of CNCT19 (2×10^6/kg) will be infused in a single-dose on day +2, +3 or +4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CNCT19</intervention_name>
    <description>2×10^6/kg, infused in a single-dose on day +2, +3 or +4 following stem-cell infusion</description>
    <arm_group_label>CNCT19 following ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Injection</intervention_name>
    <description>600mg/m2/h, infused for 3 hours with loading bolus of 75mg/m2, day -7, -3,</description>
    <arm_group_label>CNCT19 following ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>105mg/m2, day -7 until -5,</description>
    <arm_group_label>CNCT19 following ASCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan Injection</intervention_name>
    <description>60mg/m2, day -3, -2</description>
    <arm_group_label>CNCT19 following ASCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed large B-cell lymphoma including the following types&#xD;
&#xD;
               -  diffuse large B-cell lymphoma&#xD;
&#xD;
               -  high-grade B-cell lymphoma with or without MYC and BLC2 and/or BCL6 rearrangement&#xD;
&#xD;
               -  transformed lymphoma&#xD;
&#xD;
          2. Relapsed or refractory diseases fulfilling one of the following criteria (individuals&#xD;
             must have received anti-CD20 monoclonal antibody and anthracycline-containing&#xD;
             chemotherapy regimen)&#xD;
&#xD;
               -  Primary refractory disease, defined as disease progression after first-line&#xD;
                  immunochemotherapy or disease progression within 6 weeks of the end of the last&#xD;
                  chemotherapy&#xD;
&#xD;
               -  Stable disease (SD) as best response after at least 4 cycles of first-line&#xD;
                  therapy&#xD;
&#xD;
               -  Partial response (PR) as best response after at least 6 cycles of first-line&#xD;
                  therapy (biopsy-proven residual disease is needed for individuals with Deauville&#xD;
                  score of 4)&#xD;
&#xD;
               -  PR as best response after at least 2 cycles of second-line therapy&#xD;
&#xD;
               -  Disease relapse ≤12 months after the completion of first-line immunochemotherapy&#xD;
&#xD;
               -  Relapsed or refractory disease after ≥2 lines of chemotherapy&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          4. Adequate bone marrow function as evidenced by:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1000/uL&#xD;
&#xD;
               -  Platelet count≥ 75,000/uL&#xD;
&#xD;
          5. Adequate renal and hepatic function defined as:&#xD;
&#xD;
               -  Serum alanine aminotransferase (ALT/AST) ≤ 3 upper limit of normal (ULN)&#xD;
&#xD;
               -  Total bilirubin ≤1.5 mg/dL, except in individuals with Gilbert's syndrome&#xD;
&#xD;
               -  Serum creatinine ≤2 ULN, or creatinine clearance (as estimated by Cockcroft&#xD;
                  Gault) ≥ 40 mL/min&#xD;
&#xD;
          6. Cardiac ejection fraction ≥ 50%&#xD;
&#xD;
          7. Baseline oxygen saturation &gt; 92% on room air&#xD;
&#xD;
          8. Life expectancy ≥3 months&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Active Central Nervous System (CNS) involvement by lymphoma&#xD;
&#xD;
          2. History of autologous or allogeneic stem cell transplantation&#xD;
&#xD;
          3. Active HBV or HCV infection, defined as HBV-DNA or HCV-DNA levels above the normal&#xD;
             upper limit, with or without abnormal liver function. Individuals with positive HBsAg&#xD;
             or HBcAb should receive antiviral prophylaxis for at least 12 months after CNCT19&#xD;
             infusion.&#xD;
&#xD;
          4. Presence of uncontrolled infection, cardio-cerebrovascular disease，coagulopathy, or&#xD;
             connective tissue disease.&#xD;
&#xD;
          5. History of seizure or other CNS disorder&#xD;
&#xD;
          6. History of HIV infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dehui Zou, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Hematology &amp; Blood Diseases Hospital, CAMS &amp; PUMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Liu, Dr.</last_name>
    <phone>086-022-23909282</phone>
    <email>liuwei@ihcams.ac.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Liu, Dr.</last_name>
      <phone>086-022-23909282</phone>
      <email>liuwei@ihcams.ac.cn</email>
    </contact>
    <investigator>
      <last_name>Dehui Zou, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 26, 2020</study_first_submitted>
  <study_first_submitted_qc>December 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>Zou Dehui</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>autologous stem-cell transplantation</keyword>
  <keyword>anti-CD19 CAR T-cell</keyword>
  <keyword>large B-cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

